5000th patient treated with protons for eye tumours

From the patient's perspective at the treatment station: The proton beam is directed through the hole in the shield onto the tumour in the eye. The brass shield is adjusted to the individual tumour size and protects the surrounding tissue.

From the patient's perspective at the treatment station: The proton beam is directed through the hole in the shield onto the tumour in the eye. The brass shield is adjusted to the individual tumour size and protects the surrounding tissue. © HZB/. S. Kodalle

The treatment centre for eye tumour therapy in Berlin-Wannsee

The treatment centre for eye tumour therapy in Berlin-Wannsee © HZB/ S. Kodalle

For more than 25 years, Charité – Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have been jointly offering proton radiation therapy for eye tumours. The HZB operates a proton accelerator in Berlin-Wannsee for this purpose, while Charité provides medical care for the patients. The 5000th patient was treated at the beginning of August.

The treatment room and proton accelerator are specially adapted to the requirements for optimal and highly precise treatment of tumours inside the eye and are unique in this combination. The largest group of tumours in the eye is the rare and malignant uveal melanoma, which, as the name suggests, develops in the uvea of the eye.

Proton therapy is used as an effective method of fighting tumours, often as an alternative to removing the eye, with the aim of preserving the eye and its function as much as possible. The protons can be directed very precisely at the tumour, sparing the surrounding healthy tissue. Compared to other radiation methods, proton therapy causes less damage to the cornea, lens, retina and optic nerve in many cases.

8 August 2025 was a special day: it was the day on which the 5000th patient completed their eye tumour treatment. This makes the Berlin experts one of the world's leading centres: together, the two institutions (Charité and HZB) have treated 10 percent of all eye tumours treated with protons worldwide. The cooperation with Charité – Universitätsmedizin Berlin also opens up prospects for the further development of proton therapy in order to carry out even more precise and effective treatments in the future – for the benefit of patients.

(sz)

  • Copy link

You might also be interested in

  • Porous Radical Organic framework improves lithium-sulphur batteries
    Science Highlight
    15.09.2025
    Porous Radical Organic framework improves lithium-sulphur batteries
    A team led by Prof. Yan Lu, HZB, and Prof. Arne Thomas, Technical University of Berlin, has developed a material that enhances the capacity and stability of lithium-sulphur batteries. The material is based on polymers that form a framework with open pores (known as radical-cationic covalent organic frameworks or COFs). Catalytically accelerated reactions take place in these pores, firmly trapping polysulphides, which would shorten the battery life. Some of the experimental analyses were conducted at the BAMline at BESSY II.
  • Metallic nanocatalysts: what really happens during catalysis
    Science Highlight
    10.09.2025
    Metallic nanocatalysts: what really happens during catalysis
    Using a combination of spectromicroscopy at BESSY II and microscopic analyses at DESY's NanoLab, a team has gained new insights into the chemical behaviour of nanocatalysts during catalysis. The nanoparticles consisted of a platinum core with a rhodium shell. This configuration allows a better understanding of structural changes in, for example, rhodium-platinum catalysts for emission control. The results show that under typical catalytic conditions, some of the rhodium in the shell can diffuse into the interior of the nanoparticles. However, most of it remains on the surface and oxidises. This process is strongly dependent on the surface orientation of the nanoparticle facets.
  • KlarText Prize for Hanna Trzesniowski
    News
    08.09.2025
    KlarText Prize for Hanna Trzesniowski
    The chemist has been awarded the prestigious KlarText Prize for Science Communication by the Klaus Tschira Foundation.